Erasca Stock (NASDAQ: ERAS) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 789.354K |
Day Range | - - - |
52 Wk Range | 1.510 - 3.375 |
Market Cap | $295.414M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 43 |
Short Interest | 8.16% |
Days to Cover | 16.54 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Erasca (NASDAQ: ERAS) through any online brokerage.
Other companies in Erasca’s space includes: Renovaro (NASDAQ:RENB), Inozyme Pharma (NASDAQ:INZY), Adaptimmune Therapeutics (NASDAQ:ADAP), Tevogen Bio Holdings (NASDAQ:TVGN) and Opthea (NASDAQ:OPT).
The latest price target for Erasca (NASDAQ: ERAS) was reported by Goldman Sachs on Tuesday, April 2, 2024. The analyst firm set a price target for 7.00 expecting ERAS to rise to within 12 months (a possible 258.97% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Erasca (NASDAQ: ERAS) is $1.95 last updated April 24, 2024 at 4:10 PM EDT.
There are no upcoming dividends for Erasca.
Erasca’s Q1 earnings are confirmed for Monday, May 13, 2024.
There is no upcoming split for Erasca.
Erasca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.